Latigo director Walbert holds options on 259K shares

Q: What does Latigo Biotherapeutics (LTGO) disclose about Timothy P. Walbert on this Form 3?

The filing shows Timothy P. Walbert as a director of Latigo Biotherapeutics holding several director stock options. These options give him rights to acquire LTGO common shares at set exercise prices and future vesting dates.

Q: How many LTGO shares are underlying Timothy P. Walbert’s director stock options?

The options cover up to 259,770, 38,914, and 31,135 underlying LTGO common shares. Each grant has its own vesting schedule and expiration date, reflecting his potential future equity exposure as a director.

Q: What are the exercise prices of Timothy P. Walbert’s Latigo Biotherapeutics (LTGO) options?

The director stock options have exercise prices of $2.19 and $5.53 per share. These prices define the cost to acquire each share of LTGO common stock upon exercise of the respective option grants.

Q: When do Timothy P. Walbert’s LTGO director stock options expire?

The disclosed director stock options expire on 2034-10-29, 2035-02-04, and 2035-04-07. These dates mark the last day on which each option grant can be exercised to purchase LTGO common shares.

Q: How do the vesting terms work for Timothy P. Walbert’s Latigo Biotherapeutics (LTGO) options?

One grant vests in 48 equal monthly installments after October 30, 2024. Another vests 25% one year after January 28, 2025, with 1/48th monthly thereafter; all are early exercisable subject to repurchase rights.

Latigo Biotherapeutics, Inc. (LTGO) reports initial holdings for director Timothy P. Walbert on a Form 3.

Accepted by SEC EDGAR 08/06/2026 - 08:33 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Latigo Biotherapeutics, Inc. (LTGO) reports initial holdings for director Timothy P. Walbert on a Form 3. He holds director stock options to purchase common stock with exercise prices of $2.19 and $5.53, expiring between 2034-10-29 and 2035-04-07. These options cover up to 259,770, 38,914, and 31,135 underlying shares, which vest over multi-year schedules and are early exercisable, subject to the issuer’s right of repurchase.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Walbert Timothy P

Role Director

Type	Security	Shares	Price	Value
Holding	Director Stock Option (right to buy) ^F1	--	--	--
Holding	Director Stock Option (right to buy) ^F2	--	--	--
Holding	Director Stock Option (right to buy) ^F2	--	--	--

Holdings: Director Stock Option (right to buy) — 329,819 contracts (Direct)

Footnotes (2)

F1. The shares subject to this option shall vest in 48 equal monthly installments after October 30, 2024. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2. One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

Key Figures

Underlying shares (option 1): 259,770 shares Exercise price (option 1): $2.1900 per share Underlying shares (option 2): 38,914 shares +4 more

7 metrics

Underlying shares (option 1) 259,770 shares Director stock option at $2.1900 exercise price expiring 2034-10-29

Exercise price (option 1) $2.1900 per share Director stock option on LTGO common stock expiring 2034-10-29

Underlying shares (option 2) 38,914 shares Director stock option at $5.5300 exercise price expiring 2035-02-04

Exercise price (option 2) $5.5300 per share Director stock option on LTGO common stock expiring 2035-02-04

Underlying shares (option 3) 31,135 shares Director stock option at $5.5300 exercise price expiring 2035-04-07

Vesting schedule option F1 48 monthly installments Vests in 48 equal monthly installments after October 30, 2024

Cliff vesting option F2 25% after 1 year One-fourth vests one year after January 28, 2025, then 1/48th monthly

Key Terms

Director Stock Option (right to buy), early exercisable, Issuer's right of repurchase

3 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

early exercisable financial

"The shares subject to this option are early exercisable, subject to the Issuer's"

Issuer's right of repurchase financial

"early exercisable, subject to the Issuer's right of repurchase."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Latigo Biotherapeutics (LTGO) disclose about Timothy P. Walbert on this Form 3?

The filing shows Timothy P. Walbert as a director of Latigo Biotherapeutics holding several director stock options. These options give him rights to acquire LTGO common shares at set exercise prices and future vesting dates.

How many LTGO shares are underlying Timothy P. Walbert’s director stock options?

The options cover up to 259,770, 38,914, and 31,135 underlying LTGO common shares. Each grant has its own vesting schedule and expiration date, reflecting his potential future equity exposure as a director.

What are the exercise prices of Timothy P. Walbert’s Latigo Biotherapeutics (LTGO) options?

The director stock options have exercise prices of $2.19 and $5.53 per share. These prices define the cost to acquire each share of LTGO common stock upon exercise of the respective option grants.

When do Timothy P. Walbert’s LTGO director stock options expire?

The disclosed director stock options expire on 2034-10-29, 2035-02-04, and 2035-04-07. These dates mark the last day on which each option grant can be exercised to purchase LTGO common shares.

How do the vesting terms work for Timothy P. Walbert’s Latigo Biotherapeutics (LTGO) options?

One grant vests in 48 equal monthly installments after October 30, 2024. Another vests 25% one year after January 28, 2025, with 1/48th monthly thereafter; all are early exercisable subject to repurchase rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Walbert Timothy P

(Last)

(First)

(Middle)

C/O LATIGO BIOTHERAPEUTICS, INC.

1300 RANCHO CONEJO BLVD., SUITE 305

(Street)

THOUSAND OAKS

CALIFORNIA

91320

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name and Ticker or Trading Symbol
Latigo Biotherapeutics, Inc. [ LTGO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Director Stock Option (right to buy)	⁽¹⁾	10/29/2034	Common Stock	259,770	$2.19	D
Director Stock Option (right to buy)	⁽²⁾	02/04/2035	Common Stock	38,914	$5.53	D
Director Stock Option (right to buy)	⁽²⁾	04/07/2035	Common Stock	31,135	$5.53	D

Explanation of Responses:

1. The shares subject to this option shall vest in 48 equal monthly installments after October 30, 2024. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

2. One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

	/s/ Sabrina Nieder, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR